HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.

Yoshiyuki Yamaguchi(Hiroshima University), Tetsuya Toge(Hiroshima University), Makoto Okawaki, Kazuo Matsuura(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Akiko Ohshita(Hiroshima University), Riki Okita(National Sanyo Hospital), Katsuji Hironaka
PubMed
June 9, 2005
Cited by 15

Related Papers

Current status of the molecular mechanisms of anticancer drug-induced apoptosis
|Cancer Chemotherapy and Pharmacology|2002|255
The role of Fas ligand and transforming growth factor β in tumor progression
|Cancer|2004|135
Targeted therapy against Bcl-2-related proteins in breast cancer cells
|Breast Cancer Research|2005|114
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
|International Journal of Cancer|1992|111
Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy
|Cancer|2004|110